Safe Use Symposium: A Focus on Reducing Preventable Harm From Drugs in the Outpatient Setting, 18910 [2017-08182]

Download as PDF 18910 Federal Register / Vol. 82, No. 77 / Monday, April 24, 2017 / Notices ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: April 18, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation and Analysis. [FR Doc. 2017–08189 Filed 4–21–17; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2017–N–0001] Safe Use Symposium: A Focus on Reducing Preventable Harm From Drugs in the Outpatient Setting AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public symposium. The Food and Drug Administration’s (FDA or Agency) Center for Drug Evaluation and Research, Professional Affairs and Stakeholder Engagement Staff (PASES), is hosting a 1-day public symposium entitled ‘‘Safe Use Symposium: A Focus on Reducing Preventable Harm From Drugs in the Outpatient Setting.’’ The purpose of this symposium is to discuss sources of preventable harm from drugs in the outpatient setting and to stimulate the exchange of ideas among thought leaders on interventions to reduce preventable harms and how these interventions can be studied. DATES: The public symposium will be held on June 15, 2017, from 8 a.m. to 4 p.m. ADDRESSES: The public symposium will be held at FDA’s White Oak campus, 10903 New Hampshire Ave, Bldg. 31 (The Great Room C), Silver Spring, MD 20903. Entrance for the public symposium participants (non-FDA employees) is through Bldg. 1 where routine security check procedures will be performed. For parking and security information, please refer to https:// www.fda.gov/AboutFDA/ WorkingatFDA/BuildingsandFacilities/ WhiteOakCampusInformation/ ucm241740.htm. FOR FURTHER INFORMATION CONTACT: Christine Lee, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 240–402–4228, email: CDERSafeUseInitiative@fda.hhs.gov. jstallworth on DSK7TPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 13:48 Apr 21, 2017 Jkt 241001 The Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research, Professional Affairs and Stakeholder Engagement Staff (PASES), is hosting a 1-day public symposium entitled ‘‘Safe Use Symposium: A Focus on Reducing Preventable Harm From Drugs in the Outpatient Setting.’’ The purpose of this symposium is to discuss sources of preventable harm from drugs in the outpatient setting, such as the use of inappropriate medications in particular age groups, drug-drug interactions, unintended exposures, and misuse; and to stimulate the exchange of ideas among thought leaders on interventions to reduce preventable harms and how these interventions can be studied. This information may assist FDA in identifying significant and unexplored areas of preventable harm from drugs for the purpose of funding future research through the Safe Use Initiative. The symposium will feature presentations on sources of outpatient preventable harms, possible interventions, and future research topics. Areas to be discussed include identifying drugs and populations associated with a higher risk of preventable harm, as well as events which may be amenable to interventions. Methods to measure the effect of interventions and how to apply these to the outpatient setting will also be an important focus of discussion. Presenters will represent multidisciplinary backgrounds from government, academia, patient safety groups, health care industry, and clinicians. There will be opportunities for interaction between speakers and attendees as well as question and answer sessions. Registration: There is no registration fee to attend the public symposium. Early registration is recommended because seating is limited, and registration will be on a first-come, firstserved basis. There will be no onsite registration. Persons interested in attending this symposium must register online at https://wcms.fda.gov/FDAgov/ Drugs/NewsEvents/ ucm538670.htm?SSContributor=true. For those without Internet access, please contact Christine Lee (see FOR FURTHER INFORMATION CONTACT) to register. If you need special accommodations due to a disability, please contact Christine Lee at least 7 days in advance. Transcripts: A transcript of the symposium will be available for review at the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, and on the Internet at https://www.regulations.gov approximately 30 days after the SUPPLEMENTARY INFORMATION: PO 00000 Frm 00022 Fmt 4703 Sfmt 4703 symposium. Transcripts will also be available in either hard copy or on CD– ROM, after submission of a Freedom of Information request. The Freedom of Information office address is available on the Agency’s Web site at https:// www.fda.gov. Dated: April 17, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017–08182 Filed 4–21–17; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2017–N–0001] Vaccines and Related Biological Products Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). The general function of the committee is to provide advice and recommendations to the Agency on FDA’s regulatory issues. The meeting will be open to the public. DATES: The meeting will be held on May 17, 2017, from 8:30 a.m. to 4:45 p.m. ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD 20993– 0002. For those unable to attend in person, the meeting will also be Web Cast and will be available at the following link: https:// collaboration.fda.gov/rsvvaccine0517. Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: https://www.fda.gov/ AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm408555.htm. FOR FURTHER INFORMATION CONTACT: CAPT Serina Hunter-Thomas or Rosanna Harvey, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6307C, Silver Spring, MD 20993–0002, at 240– 402–5771 serina.hunter-thomas@ fda.hhs.gov and 240–402–8072, rosanna.harvey@fda.hhs.gov, or FDA SUMMARY: E:\FR\FM\24APN1.SGM 24APN1

Agencies

[Federal Register Volume 82, Number 77 (Monday, April 24, 2017)]
[Notices]
[Page 18910]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08182]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0001]


Safe Use Symposium: A Focus on Reducing Preventable Harm From 
Drugs in the Outpatient Setting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public symposium.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration's (FDA or Agency) Center for 
Drug Evaluation and Research, Professional Affairs and Stakeholder 
Engagement Staff (PASES), is hosting a 1-day public symposium entitled 
``Safe Use Symposium: A Focus on Reducing Preventable Harm From Drugs 
in the Outpatient Setting.'' The purpose of this symposium is to 
discuss sources of preventable harm from drugs in the outpatient 
setting and to stimulate the exchange of ideas among thought leaders on 
interventions to reduce preventable harms and how these interventions 
can be studied.

DATES: The public symposium will be held on June 15, 2017, from 8 a.m. 
to 4 p.m.

ADDRESSES: The public symposium will be held at FDA's White Oak campus, 
10903 New Hampshire Ave, Bldg. 31 (The Great Room C), Silver Spring, MD 
20903. Entrance for the public symposium participants (non-FDA 
employees) is through Bldg. 1 where routine security check procedures 
will be performed. For parking and security information, please refer 
to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.

FOR FURTHER INFORMATION CONTACT: Christine Lee, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Silver Spring, MD 20993-0002, 240-402-4228, email: 
CDERSafeUseInitiative@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The Food and Drug Administration's (FDA) 
Center for Drug Evaluation and Research, Professional Affairs and 
Stakeholder Engagement Staff (PASES), is hosting a 1-day public 
symposium entitled ``Safe Use Symposium: A Focus on Reducing 
Preventable Harm From Drugs in the Outpatient Setting.'' The purpose of 
this symposium is to discuss sources of preventable harm from drugs in 
the outpatient setting, such as the use of inappropriate medications in 
particular age groups, drug-drug interactions, unintended exposures, 
and misuse; and to stimulate the exchange of ideas among thought 
leaders on interventions to reduce preventable harms and how these 
interventions can be studied. This information may assist FDA in 
identifying significant and unexplored areas of preventable harm from 
drugs for the purpose of funding future research through the Safe Use 
Initiative. The symposium will feature presentations on sources of 
outpatient preventable harms, possible interventions, and future 
research topics. Areas to be discussed include identifying drugs and 
populations associated with a higher risk of preventable harm, as well 
as events which may be amenable to interventions. Methods to measure 
the effect of interventions and how to apply these to the outpatient 
setting will also be an important focus of discussion.
    Presenters will represent multidisciplinary backgrounds from 
government, academia, patient safety groups, health care industry, and 
clinicians. There will be opportunities for interaction between 
speakers and attendees as well as question and answer sessions.
    Registration: There is no registration fee to attend the public 
symposium. Early registration is recommended because seating is 
limited, and registration will be on a first-come, first-served basis. 
There will be no onsite registration. Persons interested in attending 
this symposium must register online at https://wcms.fda.gov/FDAgov/Drugs/NewsEvents/ucm538670.htm?SSContributor=true. For those without 
Internet access, please contact Christine Lee (see FOR FURTHER 
INFORMATION CONTACT) to register. If you need special accommodations 
due to a disability, please contact Christine Lee at least 7 days in 
advance.
    Transcripts: A transcript of the symposium will be available for 
review at the Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, and 
on the Internet at https://www.regulations.gov approximately 30 days 
after the symposium. Transcripts will also be available in either hard 
copy or on CD-ROM, after submission of a Freedom of Information 
request. The Freedom of Information office address is available on the 
Agency's Web site at https://www.fda.gov.

    Dated: April 17, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-08182 Filed 4-21-17; 8:45 am]
 BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.